BALTIMORE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pantheon Vision, an early-stage ophthalmic medical device company, has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI). 'We are thrilled to have KeraLink provide our initial funding to establish Pantheon Vision as a company dedicated to bringing groundbreaking ophthalmic innovations to patients worldwide,” expressed John Sheets, Ph.D., Chief Executive Officer of Pantheon Vision.

巴尔的摩医学博士，2023年11月2日（GLOBE NEWSWIRE）-早期眼科医疗器械公司Pantheon Vision宣布了来自巴尔的摩的KeraLink International（KLI）250万美元的种子融资Pantheon Vision首席执行官John Sheets博士表示，我们很高兴KeraLink能够提供我们的初步资金，将Pantheon Vision成立为致力于为全球患者带来开创性眼科创新的公司。

“This funding enables us to advance our program to eradicate corneal blindness and restore vision.” Pantheon Vision is creating bioengineered implants to raise the standard of eye care globally and reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries (LMICs).

“这项资金使我们能够推进根除角膜失明和恢复视力的计划。”万神殿愿景正在创建生物工程植入物，以提高全球眼部护理标准，减少对捐赠角膜组织的依赖，这在低收入和中等收入国家（LMICs）。

The company will engage the U.S. Food and Drug Administration (FDA) in the coming months to guide plans for global product development. The initial investment in Pantheon Vision was made by KeraLink International, a non-profit organization singularly focused on bringing clinicians, technology innovators, healthcare providers, philanthropists, and investors together to eradicate corneal blindness with an emphasis on LMICs.

该公司将在未来几个月与美国食品和药物管理局（FDA）合作，指导全球产品开发计划。最初对万神殿愿景的投资是由非营利组织KeraLink International做出的，该组织专注于将临床医生，技术创新者，医疗保健提供者，慈善家和投资者聚集在一起，消除角膜失明，重点是中低收入国家。

Doug Furlong, Chairman of the Board of Directors, KeraLink International, added, “We are pleased to have established Pantheon Vision and provided the initial funding to develop a tissue substitute to restore sight. With additional funding, Pantheon can accelerate its product development and further the KeraLink mission, which is based on the premise that being able to see should not depend on where you were born.” Pantheon Vision is led by ophthalmic industry veteran, John Sheets, Ph.D.   Dr.

KeraLink International董事会主席Doug Furlong补充说，“我们很高兴建立了万神殿愿景，并提供了开发组织替代品以恢复视力的初步资金。通过额外的资金，万神殿可以加速其产品开发并进一步推进KeraLink使命，这是基于能够看到的前提不应取决于你出生的地方。”万神殿愿景由眼科行业老兵领导，John Sheets博士。

Sheets has led companies including Hoya and Elisar, and R&D organizations at Alcon, Ba.

Sheets领导了包括Hoya和Elisar在内的公司，以及位于Ba Alcon的研发组织。